Prenetics Global Q3 2026 Earnings Preview

Prenetics Global (PRE) will report Q3 2026 earnings on November 18th. Analysts expect an EPS of -$0.90, down 69.8% year-over-year, and revenue of $63.21M, up 167.8%.

Original reporting
Published Nov 17, 2026, 5:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 5:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PRE
Neutral
medium confidence
Mentioned
$PRE
Relevance
4/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PRENeutralMed
01

Why it matters

The main trading use is expectation-setting into the earnings release, especially because consensus EPS is negative while revenue growth is projected to be strong.

02

Market read

Traders can use the consensus EPS and revenue figures to frame pre-earnings positioning and scenario analysis for the Nov. 18 open.

03

What to watch

Guidance, cash burn, and any changes in operating metrics (not provided here) could dominate the reaction versus the headline EPS and revenue consensus.

Relevance 4/10Novelty 3/10Timing: ahead of Nov. 18 pre-market Q3 earnings release

Background

The piece is a Seeking Alpha earnings preview for Prenetics Global’s Q3 2026 results, scheduled for Nov. 18 before market open.

Company-level read

Ticker impact

$PRENeutralMedium confidence
Context

Prenetics Global (PRE) is scheduled to report Q3 results Nov. 18 pre-market, with consensus EPS of -$0.90 and revenue of $63.21M.

Expected impact

Likely volatility around the Nov. 18 pre-market open as traders compare the actual EPS and revenue to the stated consensus expectations.

Evidence & confidence

The article provides consensus estimates and timing, but it does not disclose any new company-specific development beyond the scheduled earnings event.

Market effects

Limited, as this is a single-company earnings preview with no broader sector/regulatory signal.

Minimal, since the catalyst is company-specific and not a macro release.

Low, no cross-market linkage beyond general risk sentiment around earnings.

Counterpoint

If PRE’s actual revenue growth is driven by one-off factors, the market may focus more on profitability trajectory than the revenue beat implied by consensus.

Key entities

  • Prenetics Global Limited

    Subject of the preview, scheduled to report Q3 results on Nov. 18 before market open.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.